Top

CardioVascular and Interventional Radiology

Published in:

01-02-2015 | Review

Current Status of Interventional Radiology in the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)

Authors: Gianluigi Orgera, Miltiadis Krokidis, Matteo Cappucci, Sofia Gourtsoyianni, Marcello Andrea Tipaldi, Adam Hatzidakis, Alberto Rebonato, Michele Rossi

Published in: CardioVascular and Interventional Radiology | Issue 1/2015

Abstract

Within the group of Gastro-Entero-Pancreatic Neuroendocrine tumours (GEP-NETs), several heterogeneous malignancies are included with a variety of clinical manifestations and imaging characteristics. Often these cases are inoperable and minimal invasive treatment offered by image-guided procedures appears to be the only option. Interventional radiology offers a valid solution in the management of primary and metastatic GEP-NETs. The purpose of this review article is to describe the current status of the role of Interventional Radiology in the management of GEP-NETs.

Amodio A, Crosetti S (2010) Tumori Neuroendocrini. In: Lopez M, Gebbia N, Cascinu S, Marchetti P (eds) Oncologia Medica Pratica. Società Editrice Universo, Roma, pp 2173–2194

Muniraj T, Vignesh S, Shetty S et al (2013) Pancreatic neuroendocrine tumor. Dis Mon 59:5–19PubMedCrossRef

Colao A, Faggiano A, Milone F (2011) Tumori Neuroendocrini. In: Lenzi A, Lom-bardi G, Martino E, Vigneri R (eds) Endocrinologia Clinica. Edizioni Minerva Medica, Torino, pp 217–224

Klöppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocrine Related Cancer 18:S1–S16PubMedCrossRef

Bosman FT, Carneiro F, Hruban R et al (2010) WHO classification of tumours of the digestive system. IARC Press, Lyon

Klimstra DS, Modlin IR, Coppola D et al (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39:707–712PubMedCrossRef

Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072PubMedCrossRef

Burns WR, Edil BH (2011) Neuroendocrine pancreatic tumors: guidelines for management and update. Curr Treat Options Oncol 13:24–34CrossRef

Orgera G, Krokidis M, Monfardini L et al (2011) High intensity focused ultrasound ablation of pancreatic neuroendocrine tumours: report of two cases. Cardiovasc Intervent Radiol 34:419–423PubMedCrossRef

10.

Drymousis P, Raptis DA, Spalding D et al (2014) Laparoscopic versus open pancreas resection for pancreatic neuroendocrine tumours: a systematic review and meta-analysis. HPB (Oxford) 16(5):397–406CrossRef

11.

Rossi RE, Massironi S, Spampatti MP, Conte D, Ciafardini C, Cavalcoli F, Peracchi M (2012) Treatment of liver metastases in patients with digestive neuroendocrine tumors. J Gastrointest Surg. 16(10):1981–1992PubMedCrossRef

12.

Oberg K, Knigge U, Kwekkeboom D, ESMO Guidelines Working Group et al (2012) Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23(Suppl 7):vii124–vii130PubMed

13.

Pavel M, Baudin E, Couvelard A et al (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157–176PubMedCrossRef

14.

Ramage JK, Ahmed A, Ardill J, UK and Ireland Neuroendocrine Tumour Society et al (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NET’s). Gut 61(1):6–32PubMedCentralPubMedCrossRef

15.

Gouya H, Vignaux O, Augui J et al (2003) CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 181(4):987–992PubMedCrossRef

16.

Arnold R, Chen YJ, Costa F, Mallorca Consensus Conference participants, European Neuroendocrine Tumor Society et al (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 90(2):227–233PubMedCrossRef

17.

Campana D, Nori F, Piscitelli L et al (2007) Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 25(15):1967–1973PubMedCrossRef

18.

Arnold R, Wilke A, Rinke A et al (2008) Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 6(7):820–827PubMedCrossRef

19.

Kulke MH, Benson AB III, Bergsland E et al (2012) Neuroendocrine tumors. J Natl Compr Cancer Netw 10:724–764

20.

Peppa M, Brountzos E, Economopoulos N et al (2009) Embolization as an alternative treatment of insulinoma in a patient with multiple endocrine neoplasia type 1 syndrome. Cardiovasc Intervent Radiol 32:807–811PubMedCrossRef

21.

Moore T, Peterson L, Harington D (1982) Successful arterial embolization of an insulinoma. JAMA 248:1953–1955CrossRef

22.

Uflacker R (1992) Arterial embolization as definitive treatment for benign insulinoma of the pancreas. J Vasc Interv Radiol 3:441–639 discussion 644–666CrossRef

23.

Rott G, Biggemann M, Pfohl M (2008) Embolization of an insulinoma of the pancreas with trisacryl gelatin microspheres as definitive treatment. Cardiovasc Intervent Radiol 31:659–662PubMedCrossRef

24.

Ben-Ishay O, Linder R, Ofer A et al (2012) Hypervascular lesion in the head of the pancreas. Preoperative angiography and selective embolization results in bloodless operation. JOP 13:671–673PubMed

25.

Rossi M, Orgera G, Hatzidakis A et al (2014) Minimally invasive ablation treatment for locally advanced pancreatic adenocarcinoma. Cardiovasc Intervent Radiol 37:203–210PubMedCrossRef

26.

Goldberg SN, Mallery S, Gazelle GS et al (1999) EUS-guided radiofrequency ablation in the pancreas: results in a porcine model. Gastrointest Endosc 50:392–401PubMedCrossRef

27.

Date RS, Biggins J, Paterson I et al (2005) Development and validation of an experimental model for the assessment of radiofrequency ablation of pancreatic parenchyma. Pancreas 30:266–271PubMedCrossRef

28.

Matsui Y, Nakagawa A, Kamiyama Y et al (2000) Selective thermocoagulation of unresectable pancreatic cancers by using radiofrequency capacitive heating. Pancreas 20:14–20PubMedCrossRef

29.

Limmer S, Huppertb P, Juettea V et al (2009) Radiofrequency ablation of solitary pancreatic insulinoma in a patient with episodes of severe hypoglycemia. Eur J Gastroenterol Hepatol 21:1097–1101PubMedCrossRef

30.

Akhlaghpoor S, Dahi F, Alinaghizadeh M et al (2011) CT fluoroscopy-guided transcaval radiofrequency ablation of insulinoma. J Vasc Interv Radiol 22:409–410PubMedCrossRef

31.

Wu P, Pan C, Huang Z et al (2010) Percutaneous radiofrequency ablation approach through the spleen: initial case report for pancreatic tail gastrinoma. Chin J Cancer 29:836–841PubMedCrossRef

32.

Hlavsa J, Procházka V, Kala Z et al (2011) Radiofrequency ablation of pancreatic neuroendocrine tumor. Klin Onkol 24:209–215PubMed

33.

Fegrachi S, Besselink MG, van Santvoort HC et al (2014) Radiofrequency ablation for unresectable locally advanced pancreatic cancer: a systematic review. HPB (Oxford) 16:119–123CrossRef

34.

Chen Q, Zhu X, Chen Q et al (2013) Unresectable giant pancreatic neuro-endocrine tumor effectively treated by HIFU: a case report and a review of the literature. Pancreatology 13:634–638PubMedCrossRef

35.

Dunki-Jacobs EM, Philips P, Martin RC 2nd (2014) Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. J Am Coll Surg 218(2):179–187PubMedCrossRef

36.

Scheffer HJ, Nielsen K, de Jong MC et al (2014) Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol 25(7):997–1011PubMedCrossRef

37.

Mayo SC, De Jong MC, Pulitano C et al (2010) Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 17:3129–3136PubMedCrossRef

38.

John BJ, Davidson BR (2012) Treatment options for unresectable neuroendocrine liver metastases. Expert Rev Gastroenterol Hepatol 6:357–369PubMedCrossRef

39.

Frilling A, Sotiropoulos GC, Li J et al (2010) Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 12:361–379CrossRef

40.

McDermott EW, Guduric B, Brennan MF (1994) Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 81:1007–1009PubMedCrossRef

41.

Zeitels J, Naunheim K, Kaplan EL et al (1982) Carcinoid tumors: a 37-year experience. Arch Surg 117:732–737PubMedCrossRef

42.

Panzuto F, Merola E, Rinzivillo M et al (2014) Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. Pancreas 43:212–218PubMedCrossRef

43.

Dromain C, de Baere T, Baudin E et al (2003) MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 180(1):121–128PubMedCrossRef

44.

Gupta S, Johnson MM, Murthy R et al (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104:1590–1602PubMedCrossRef

45.

Strosberg JR, Choi J, Cantor AB et al (2006) Selective hepatic artery embolization for treatment of patients with meta-static carcinoid and pancreatic endocrine tumors. Cancer Control 13:72–78PubMed

46.

Sofocleous CT, Petre EN, Gonen M et al (2013) Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases. J Vasc Interv Radiol 25:22–30CrossRef

47.

Kress O, Wagner HJ, Wied M et al (2003) Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors—a retrospective single-center analysis. Digestion 68:94–101PubMedCrossRef

48.

Korse CM, Bonfrer JM, Prevoo W et al (2011) Increase of angiogenic growth factors after hepatic artery embolization in patients with neuroendocrine tumours. Tumour Biol 32(4):647–652PubMedCrossRef

49.

Liao XF, Yi JL, Li XR et al (2004) Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J Gastroenterol 10(13):1885–1889PubMed

50.

Strosberg JR, Weber JM, Choi J et al (2012) A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol 23(9):2335–2341PubMedCrossRef

51.

Ruutiainen AT, Soulen MC, Tuite CM et al (2007) Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 18:847–855PubMedCrossRef

52.

Pitt SC, Knuth J, Keily JM et al (2008) Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg 12:1951–1960PubMedCentralPubMedCrossRef

53.

Maire F, Lombard-Bohas C, O’Toole D et al (2012) Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases of well-differentiated midgut endocrine tumors. A prospective randomized study. Neuroendocrinology 96:294–300PubMedCrossRef

54.

Fiore F, Del Prete M, Franco R et al (2014) Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine 47(1):177–182PubMedCrossRef

55.

De Baere T, Deschamps F, Teriitheau C et al (2008) Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 19:855–861PubMedCrossRef

56.

Gaur SK, Friese JL, Sadow CA et al (2011) Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol 34:566–572PubMedCrossRef

57.

Bhagat N, Reyes DK, Lin M et al (2013) Phase II study of chemoembolization with drug-elutingbeads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol 36:449–459PubMedCentralPubMedCrossRef

58.

Guiu B, Deschamps F, Aho S et al (2012) Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol 56(3):609–617PubMedCrossRef

59.

Kennedy AS, Dezarn WA, McNeillie P et al (2008) Radioembolization for unresectable neuroendocrine hepatic metastases using resin ⁹⁰Y-microspheres: early results in 148 patients. Am J Clin Oncol 31:271–279PubMedCrossRef

60.

King J, Quinn R, Glenn DM et al (2008) Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113:921–929PubMedCrossRef

61.

Cao CQ, Yan TD, Bester L et al (2010) Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 97:537–543PubMedCrossRef

62.

Saxena A, Chua TC, Bester L et al (2010) Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 251:910–916PubMedCrossRef

63.

Kalinowski M, Dressler M, Konig A et al (2009) Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 79:137–142PubMedCrossRef

64.

Paprottka PM, Hoffmann RT, Haug A et al (2012) Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol 35:334–342PubMedCrossRef

65.

Rhee TK, Lewandowski RJ, Liu DM et al (2008) ⁹⁰Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 247:1029–1035PubMedCrossRef

66.

Jansen MC, Van Hillegersberg R, Schoots IG et al (2010) Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser induced thermotherapy in a rat liver model. Surgery 147:686–695PubMedCrossRef

67.

Vyleta M, Coldwell D (2011) Radioembolization in the treatment of neuroendocrine tumor metastases to the liver. Int J Hepatol 2011:785315PubMedCentralPubMedCrossRef

68.

Limouris GS, Chatziioannou A, Kontogeorgakos D et al (2008) Selective hepatic arterial infusion of In-111-DTPA-Phe1octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 35(10):1827–1837PubMedCrossRef

69.

Auernhammer CJ, Goke B (2011) Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 60:1009–1021PubMedCrossRef

70.

Akyildiz HY, Mitchell J, Milas M et al (2010) Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 148:1288–1293PubMedCrossRef

71.

Mazzaglia PJ, Berber E, Milas M et al (2007) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142:10–19PubMedCrossRef

72.

Martin RC, Scoggins CR, McMasters KM (2010) Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol 17:171–178PubMedCrossRef

73.

Groeschl RT, Pilgrim CH, Hanna EM et al (2013) Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg 259(2):1195–1200

74.

Shapiro RS, Shafir M, Sung M et al (1998) Cryotherapy of metastatic carcinoid tumors. Abdom Imaging 23:314–317PubMedCrossRef

75.

Seifert JK, Cozzi PJ, Morris DL (1998) Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 14:175–183PubMedCrossRef

76.

Bilchik AJ, Sarantou T, Foshag LJ et al (1997) Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 122:1040–1047 discussion 1047–1048PubMedCrossRef

77.

Seifert JK, Morris DL (1999) World survey on the complications of hepatic and prostate cryotherapy. World J Surg 1923:109–113 discussion 113–114CrossRef

Title: Current Status of Interventional Radiology in the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)
Authors: Gianluigi Orgera
Miltiadis Krokidis
Matteo Cappucci
Sofia Gourtsoyianni
Marcello Andrea Tipaldi
Adam Hatzidakis
Alberto Rebonato
Michele Rossi
Publication date: 01-02-2015
Publisher: Springer US
Published in: CardioVascular and Interventional Radiology / Issue 1/2015
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-014-1005-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Current Status of Interventional Radiology in the Management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Isolated Calyx Mistaken for a Cyst: Inappropriately Performed Catheter-Directed Sclerotherapy and Safe Removal of the Catheter After Selective Embolization

A Newly Designed Stent for Management of Malignant Distal Duodenal Stenosis

Diagnosis and Management of Budd Chiari Syndrome: An Update

Sustained Benefit at 2 Years for Covered Stents Versus Bare-Metal Stents in Long SFA Lesions: The VIASTAR Trial

Perfusion Angiography of the Foot in Patients with Critical Limb Ischemia: Description of the Technique

Reply: Interventional Options to Treat Postoperative Duodenal Stump Leaks